Park Avenue Securities LLC and
Swiss National Bank have recently sold
56 shares and
an undisclosed amount of shares respectively, of
Bio-Rad Laboratories, Inc. (NYSE:BIO), while
Harbor Capital Advisors Inc. procured
2,792 shares.
GAMMA Investing LLC and
Tidal Investments LLC both increased their stake, and
Swedbank has recently purchased a new position. However,
Bio-Rad Laboratories’ stocks encountered decline by
14% lately leading to a total
53% loss over three years. Despite this,
Bio-Rad Laboratories shares surged
7.8% after its last earnings report and Q2 earnings surpassed estimates. Yet,
Bio-Rad Laboratories reported a loss of
US$76.26 per share in the second quarter of 2024. In partnership news, a swift post-market climb was seen in
Oncocyte stock following the announcement of its partnership with
Bio-Rad. Alongside this,
Bio-Rad Laboratories has announced a
$500M share repurchase program. However, the company has unexpectedly lowered full-year guidance due to a 3% drop in net sales for Q1. While there's a rumored $10 Billion Qiagen buyout, it seems unlikely. Yet, Business returns aren't deemed economically valuable as the Sartorius portfolio is regarded as a hindrance.
Bio-Rad Laboratories Stocks News Analytics from Wed, 27 Jun 2018 01:17:35 GMT to Sun, 11 Aug 2024 11:10:49 GMT -
Rating -3
- Innovation 1
- Information 6
- Rumor -5
